{
    "ticker": "FCRX",
    "name": "Forte Biosciences, Inc.",
    "description": "Forte Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for severe diseases. Founded in 2015, Forte aims to address unmet medical needs through its groundbreaking research in immunology and regenerative medicine. The company is primarily engaged in the development of advanced therapies for patients suffering from rare genetic disorders. Forte's lead product candidate, FB-401, is designed to treat patients with a rare autoimmune disease, utilizing a proprietary approach that aims to restore immune balance and function. Forte's commitment to scientific excellence is reflected in its collaborations with leading academic institutions and research organizations, enabling the company to stay at the forefront of biomedical innovation. The company's mission is to transform the lives of patients through the development of safe and effective therapies, leveraging cutting-edge science and technology. With a strong pipeline and a dedicated team of experts in drug development, Forte Biosciences is positioned to make significant contributions to the field of biotechnology.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Los Angeles, California, USA",
    "founded": "2015",
    "website": "https://fortebiosciences.com",
    "ceo": "Dr. Paul L. N. McCarthy",
    "social_media": {
        "twitter": "https://twitter.com/ForteBiosci",
        "linkedin": "https://www.linkedin.com/company/forte-biosciences/"
    },
    "investor_relations": "https://investors.fortebiosciences.com",
    "key_executives": [
        {
            "name": "Dr. Paul L. N. McCarthy",
            "position": "CEO"
        },
        {
            "name": "Dr. David G. L. Kauffman",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Therapeutics",
            "products": [
                "FB-401"
            ]
        }
    ],
    "seo": {
        "meta_title": "Forte Biosciences, Inc. | Innovative Therapies for Severe Diseases",
        "meta_description": "Learn about Forte Biosciences, Inc., a clinical-stage biopharmaceutical company focused on developing novel therapies for rare genetic disorders and autoimmune diseases.",
        "keywords": [
            "Forte Biosciences",
            "Biotechnology",
            "Pharmaceuticals",
            "Autoimmune Diseases",
            "Rare Genetic Disorders"
        ]
    },
    "faq": [
        {
            "question": "What is Forte Biosciences known for?",
            "answer": "Forte Biosciences is known for developing innovative therapies for severe diseases, focusing on rare genetic disorders and autoimmune diseases."
        },
        {
            "question": "Who is the CEO of Forte Biosciences?",
            "answer": "Dr. Paul L. N. McCarthy is the CEO of Forte Biosciences, Inc."
        },
        {
            "question": "Where is Forte Biosciences headquartered?",
            "answer": "Forte Biosciences is headquartered in Los Angeles, California, USA."
        },
        {
            "question": "What is Forte's lead product candidate?",
            "answer": "Forte's lead product candidate is FB-401, aimed at treating a rare autoimmune disease."
        },
        {
            "question": "When was Forte Biosciences founded?",
            "answer": "Forte Biosciences was founded in 2015."
        }
    ],
    "competitors": [
        "CRSP",
        "EDIT",
        "SGMO"
    ],
    "related_stocks": [
        "AMGN",
        "GILD",
        "VRTX",
        "REGN"
    ]
}